Orthocell has today announced that our exclusive global distribution partner BioHorizons has officially completed first sales of Orthocell’s dental product, Striate+™, in Germany, Austria and Switzerland – also known as the ‘DACH’ region.
As an established distributor in the DACH market, this launch forms part of BioHorizons’ established European market penetration strategy which continues to achieve robust sales growth in a targeted addressable market valued at over AU$285 million..
Global sales are now gaining pace, driven by positive feedback from dental surgeons using the Striate+ dental implant.
Orthocell is now working with BioHorizons to fast track its expansion into several other large new international markets, including Brazil where approval is expected within the next three months.
Click to read the ASX release.